“Useful comparison, but not carefully done.”
Post# of 148165
(Total Views: 736)
Posted On: 07/25/2020 9:22:19 PM
Re: Borel Fields #45018
“Useful comparison, but not carefully done.”
After rereading my post, I should’ve been more clear: we know CYDY unblinded the data on Friday the 17th of July and released efficacy data 4 days later. I made an assumption that Synairgen unblinded shortly after the last patient was complete and this analyzed the data for a number of weeks.
Regardless, NP said himself that the analysis of trial data typically takes much longer and his comment matches with that of other data releases, regardless of my above assumptions. NP should’ve never promised a PR Tuesday nor should he have published a PR with inconsistent terminology that confused the masses. My point: CYDY and Amarex need to check the data twice, looking for who’s been naughty or nice, and then publish a clear and concise PR.
After rereading my post, I should’ve been more clear: we know CYDY unblinded the data on Friday the 17th of July and released efficacy data 4 days later. I made an assumption that Synairgen unblinded shortly after the last patient was complete and this analyzed the data for a number of weeks.
Regardless, NP said himself that the analysis of trial data typically takes much longer and his comment matches with that of other data releases, regardless of my above assumptions. NP should’ve never promised a PR Tuesday nor should he have published a PR with inconsistent terminology that confused the masses. My point: CYDY and Amarex need to check the data twice, looking for who’s been naughty or nice, and then publish a clear and concise PR.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼